Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: Hormonal changes can have a major effect on seizure disorders
dc.contributor.author | Aydin S. | |
dc.contributor.author | Dag E. | |
dc.contributor.author | Ozkan Y. | |
dc.contributor.author | Erman F. | |
dc.contributor.author | Dagli A.F. | |
dc.contributor.author | Kilic N. | |
dc.contributor.author | Sahin I. | |
dc.contributor.author | Karatas F. | |
dc.contributor.author | Yoldas T. | |
dc.contributor.author | Barim A.O. | |
dc.contributor.author | Kendir Y. | |
dc.date.accessioned | 2024-07-22T08:21:52Z | |
dc.date.available | 2024-07-22T08:21:52Z | |
dc.date.issued | 2009 | |
dc.description.abstract | Nesfatin-1 and ghrelin are the two recently discovered peptide hormones involved in the control of appetite. Besides its main appetite-control function, ghrelin also has anticonvulsant effects, while nesfatin-1 causes depolarization in the paraventricular nucleus (PVN). The aims of this study, therefore, were to investigate: (i) whether there are differences in the concentrations of nesfatin-1 and ghrelin in saliva and serum samples between eplilepsy patients and normal controls and (ii) whether salivary glands produce nesfatin-1. The study included a total of 73 subjects: 8 patients who were newly diagnosed with primary generalized seizures and had recently started antiepileptic drug therapy; 21 who had primary generalized seizures and were continuing with established antiepileptic drug therapy; 24 who had partial seizures (simple: n = 12 or complex: n = 12) and were continuing with established antiepileptic drug therapy; and 20 controls. Salivary gland tissue samples were analyzed for nesfatin-1 expression by immunochemistry and ELISA. Saliva and serum ghrelin levels were measured by ELISA and RIA, and nesfatin-1 levels by ELISA. Nesfatin-1 immunoreactivity was detected in the striated and interlobular parts of the salivary glands and the ducts. The nesfatin-1 level in the brain was around 12 times higher than in the salivary gland. Before antiepileptic treatment, both saliva and serum nesfatin-1 levels were around 160-fold higher in patients who are newly diagnosed with primary generalized epilepsy (PGE) than in controls; these levels decreased with treatment but remained about 10 times higher than the control values. Saliva and serum nesfatin-1 levels from patients with PGE and partial epilepsies who were continuing antiepileptic drugs were also 10-fold higher than control values. Serum and saliva ghrelin levels were significantly (twofold) lower in epileptic patients before treatment than in controls; they recovered somewhat with treatment but remained below the control values. These results suggest that the low ghrelin and especially the dramatically elevated nesfatin-1 levels might contribute to the pathophyisology of epilepsy. Therefore, serum and saliva ghrelin and especially the remarkably increased nesfatin-1 might be candidate biomarkers for the diagnosis of epilepsy and for monitoring the response to anti-epileptic treatment. © Springer Science+Business Media, LLC. 2009. | |
dc.identifier.DOI-ID | 10.1007/s11010-009-0073-x | |
dc.identifier.issn | 15734919 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18807 | |
dc.language.iso | English | |
dc.subject | Adolescent | |
dc.subject | Adult | |
dc.subject | Anticonvulsants | |
dc.subject | Biological Markers | |
dc.subject | Case-Control Studies | |
dc.subject | Epilepsies, Partial | |
dc.subject | Epilepsy | |
dc.subject | Female | |
dc.subject | Ghrelin | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Nerve Tissue Proteins | |
dc.subject | Peptide Hormones | |
dc.subject | Saliva | |
dc.subject | Salivary Glands | |
dc.subject | Young Adult | |
dc.subject | carbamazepine | |
dc.subject | ghrelin | |
dc.subject | nesfatin 1 | |
dc.subject | peptide hormone | |
dc.subject | phenytoin | |
dc.subject | unclassified drug | |
dc.subject | valproic acid | |
dc.subject | adult | |
dc.subject | article | |
dc.subject | brain level | |
dc.subject | controlled study | |
dc.subject | enzyme linked immunosorbent assay | |
dc.subject | epilepsy | |
dc.subject | female | |
dc.subject | focal epilepsy | |
dc.subject | grand mal seizure | |
dc.subject | hormone action | |
dc.subject | hormone blood level | |
dc.subject | hormone synthesis | |
dc.subject | human | |
dc.subject | human tissue | |
dc.subject | immunohistochemistry | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | protein expression | |
dc.subject | protein localization | |
dc.subject | radioimmunoassay | |
dc.subject | saliva level | |
dc.subject | salivary gland | |
dc.subject | salivary gland duct | |
dc.subject | tissue distribution | |
dc.subject | treatment response | |
dc.title | Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: Hormonal changes can have a major effect on seizure disorders | |
dc.type | Article |